Propanc Biopharma Receives Nasdaq Delisting Notice
Nasdaq said Propanc Biopharma failed to meet the $1.00 minimum bid price requirement and is ineligible for a standard compliance period following a recent reverse stock split.
On October 23, 2026, Propanc Biopharma received notice from Nasdaq that its stock did not meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that it is ineligible for a standard compliance period because of a recent reverse stock split. Nasdaq said the securities…